Manufactures and sells health, hygiene, and nutrition products. Offers disinfection and hygiene products under the Dettol and Lysol brands. Now — the numbers.
This is an established company with proven profits.
No real growth (1% a year). Red columns mark years that ended in a loss.
The gap is $8.7B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 10.3× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 44% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 22% — still a thick cushion, though costs have been eating into it lately.
It pays out $1.21 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales grew only 1% a year on average. At this size, speeding back up is not easy.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Against everything we grade, RBGLY lands near the bottom. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RBGLY does earn real profits — but on our report card it still sits behind its class. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
Not covered, because the filings we hold do not carry it: the revenue breakdown.